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KESAN ANTIPROLIFERASI EKSTRAK QUERCUS INFECTORIA DAN 
MEKANISME KEMATIAN KEPADA SEL KANSER SERVIK (HELA)  
 
ABSTRAK 
 
Kanser merupakan salah satu penyakit yang menjadi punca utama kematian di 
seluruh dunia. Sehingga kini kebanyakan kaedah rawatan yang sedia ada 
memudaratkan dan mendatangkan kesan sampingan terhadap pesakit. Oleh kerana 
itu, pesakit mula mencari penyelesaian alternatif seperti menggunakan ubat-ubatan 
herba. Sumber-sumber bertulis telah membuktikan Q. infectoria (QI) mempunyai 
pelbagai sifat terapeutik termasuk aktiviti antikanser. Walau bagaimanapun, 
mekanisme di sebalik aktiviti antikansernya tidak dijelaskan dengan terperinci. 
Justeru, dalam kajian ini, QI telah dipilih untuk diuji aktiviti antiproliferasi dan mod 
tindakbalasnya. Aktiviti antiproliferasi ekstrak akuas (QIA) dan ekstrak etanol  (QIE) 
Q. infectoria terhadap sel kanser servik (HeLa), sel kanser ovari (Caov-3) dan sel 
kanser hati (HepG-2) ditentukan melalui kaedah asai metilina biru (MBA). Aktiviti 
antiproliferasi ekstrak terhadap sel ginjal normal (Vero) dan sel fibroblast normal 
(L929) juga diperiksa untuk melihat kesan toksik dan keselektifan ekstrak. Di 
samping itu, sel yang dirawat dengan DMSO berfungsi sebagai kawalan negatif dan 
sisplatin sebagai kawalan positif. Kemudian, graf dos-tindak balas diplot bagi 
menentukan nilai IC50. Kemudian, mekanisme kematian sel terawat-QIA diperiksa 
melalui pewarnaan Hoechst 33258, pewarnaan berganda FITC-annexin V/propidium 
iodida dan pengesanan protein apoptosis. Selain itu, pemeriksaan kandungan 
fitokimia, ujian antioksidan serta analisis jumlah kandungan fenolik juga dijalankan 
untuk melihat hubung kait aktiviti biologi. Keputusan kajian menunjukkan QIA 
xx 
 
mempunyai aktiviti antiproliferasi yang lebih baik berbanding QIE dengan 
perencatan pertumbuhan paling baik kepada sel HeLa (nilai IC50 = 13.64 ± 2.39 
µg/ml) dan bersifat sitoselektif.  Hasil kajian juga menunjukkan sel HeLa yang 
dirawat dengan QIA menjalani apoptosis, dibuktikan melalui perubahan pada 
morfologi nukleus dan kehadiran jasad apoptotik serta peningkatan pada kadar 
apoptosis. Tambahan, hasil menunjukkan QIA mencetus apoptosis melalui tapak 
jalan-p53. Peningkatan aras p53 dilihat menurunkan aras Bcl-2 dan meransang 
pembebasan sitokrom c, seterusnya apoptosis dilaksanakan melalui pengaktifan 
caspase-3. Walau bagaimanapun, tiada perubahan pada ekspresi Bax dikesan dalam 
kajian ini. Berdasarkan ujian pengesanan kandungan fitokimia, QIA didapati 
mengandungi tannin, flavanoid dan alkaloid. Malah, daripada ujian antioksidan QIA 
mempamerkan aktiviti pemerangkapan radikal DPPH dan superoksida X/XOD yang 
hebat serta mempunyai jumlah kandungan fenolik yang tinggi. Kesan antiproliferasi 
QIA mungkin disumbangkan oleh kepelbagaian sebatian yang bertindak sebagai 
agen antioksidan yang kuat. Secara kesimpulannya, QIA mencetus apoptosis dalam 
menjalankan aktiviti antiproliferasi yang selektif terhadap sel kanser. 
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ANTIPROLIFERATIVE EFFECTS OF QUERCUS INFECTORIA GALLS 
EXTRACT AND ITS MECHANISM OF CELL DEATH ON CERVICAL 
CANCER (HELA) CELLS 
 
ABSTRACT 
 
Cancer is one of the leading causes of death worldwide. To date, most of the 
available therapies are detrimental and cause side effects to the patients. Therefore, 
patients turn to alternative treatments by utilizing herbs. Accumulating evidences 
have shown the wide range of therapeutics properties of Q. infectoria (QI) galls 
including anticancer activity. However, the mechanism of action was not well 
explained. Therefore, in this study, QI galls were selected for the evaluation of 
antiproliferative activity and mode of action. The antiproliferative activity of Q. 
infectoria galls aqueous extract (QIA) and ethanol extract (QIE) against cervical 
cancer (HeLa), ovarian cancer (Caov-3) and liver cancer (HepG-2) cell lines has 
been accessed by methylene blue assay. The antiproliferative activity towards normal 
kidney (Vero) and normal fibroblast (L929) cells were also evaluated to determine 
the toxic effects and selective property of the extracts. In addition, cells treated with 
DMSO served as negative control and cisplatin as positive control. Dose-response 
curve were then constructed to determine the IC50 values. Then, the mode of cell 
death in QI-treated cells was determined by Hoechst 33258 staining, FITC-annexin 
V/propidium iodide double staining and detection of apoptotic proteins. Besides, 
phytochemicals screening, antioxidant tests and total phenolic content analysis were 
done to observe the connection of bioactivity. From the results, as compared to QIE, 
QIA showed better antiproliferative activity with best growth inhibition towards 
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HeLa cells (IC50 value = 13.64 ± 2.39 µg/ml) and exhibit cytoselective property. This 
current finding also showed that HeLa cells treated with QIA undergone apoptosis, 
represented by the alteration of nuclear morphology and presence of apoptotic bodies 
as well increased rate of apoptosis. Moreover, results have shown that QIA induced 
apoptosis through p53-dependant pathway. Upregulation of p53 has been observed to 
downregulate Bcl-2 and promoted secretion of cytochrome c, thus facilitated the 
execution of apoptosis through caspase-3 activation. However, no alteration of Bax 
expression was detected in this study. Based on the phytochemicals screening, QIA 
comprises of tannin, flavanoid and alkaloid. Furthermore, the antioxidant profiles 
showed that QIA exhibited great DPPH radical scavenging and X/XOD superoxide 
scavenging activities and contains high total phenolic contents. The antiproliferative 
activity of QIA might be contributed by the diversity of compounds that act as strong 
antioxidants. From this study, we can conclude that QIA exhibited its selective 
antiproliferative activity against HeLa cells by induction of apoptotic cell death. 
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 CHAPTER 1 
 
INTRODUCTION 
 
1.1 Study background 
Chemotherapy is one of the leading approaches among cancer therapies, which 
involves the utilization of selection of drugs to control advance stages of 
malignancies and as a prophylactic against promising metastasis (Raguz and Yague, 
2008; Sarkar and Li, 2009; Caley and Jones, 2012). Despite the achievement made in 
the improvement of effective chemotherapy drugs, their toxicity to normal tissues 
and adverse side effects in multiple organ systems as well as drug resistance, have 
remained the main barriers for the successful clinical application (Sak, 2012).  
 
As a result, cancer remains a major contributor to mortality worldwide (American 
Cancer Society, 2011). According to GLOBOCAN (2008), cervical and liver cancers 
are among the two most common types of cancer diagnosed and two most leading 
cancer deaths in men and women in several continents of the world (American 
Cancer Society, 2011). Meanwhile, ovarian cancer which listed as fifth most 
common cause of cancer death in women represents as the most deadly gynecologic 
cancer in 2012 (Hoffman et al., 2012). In 2008, these types (cervical, ovarian and 
liver) of cancer have been estimated as top ten most death causing cancer in 
developing countries (American Cancer Society, 2011). 
 
This worrying phenomenon has encouraged many researchers to search for new 
anticancer agent. In this attempt, natural sources get extra attention by 
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pharmacologists and biochemists in the development of potential chemotherapeutic 
agents (Abad and Bermejo, 2001; Gurib-Fakim, 2006). All over the ages, nature has 
become important sources in providing basic needs for human daily life (Gurib-
Fakim, 2006). The consumption of nature not only limited as a source of food even 
more than that, it also plays a role in the preparations of traditional medicines for 
thousand years to alleviate diseases and for health maintenance (Gurib-Fakim, 2006; 
McChesney et al., 2007).  
 
Plant derived natural sources have a long history usage in traditional medicinal 
systems, which served as integral elements in the preparation of remedies by 
traditional practitioners of ayuverda, traditional Chinese medicine, siddha and 
ancient Egypt system to treat various ailments (Cai et al., 2004; Wilson et al., 2007; 
Meena et al., 2009; Aboelsoud, 2010). Even in 21st century, the therapeutic values of 
plants still treasured by modern people, with 80% of world population rely on plant-
based therapy for their primary healthcare (Farnsworth, 1985; Meena et al., 2009).  
 
As a rich sources of therapeutic agents for the treatment of diseases and ailments, 
plants has been accepted as complementary and alternative medicine (CAM) to cure 
several illness including cancer (Yin et al., 2013). In United States of America 
(USA), plants constitute 30-75% of used CAM by most cancer patients (Richardson, 
2001). According to epidemiologist, daily intake of plant rich phytochemicals can 
reduce the prevalence of certain types of cancers (Sporn and Suh, 2002; Surh, 2003; 
D'Incalci et al., 2005; Russo et al., 2005). By acting as antioxidants, several 
phytochemicals present in plants such as vitamins (A, C, E, K), carotenoids, 
terpenoids, flavonoids, polyphenols, alkaloids, tannins, saponins, pigments, enzymes 
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and minerals protect the body cells from being damaged by free radicals leading to 
the anticancer activity (Heber, 2004; Madhuri and Pandey, 2009). 
 
The traditional and folk practices have provided clues and knowledges which lead to 
the discovery and emergence of plant-derived chemotherapeutic drugs. This 
nutritional approach has brought a new direction to raise cancer therapy by means of 
reducing the adverse side effects and improve the effectiveness of chemotherapeutic 
drugs. For example, drugs like vinblastine, vincristine, taxol, and camptothecin 
isolated from different species of plants have improved the chemotherapy of some 
cancers (Newman et al., 2003).  
 
Since the introduction of in vitro prescreening programme in 1986, research area has 
been witnessed with the growing number of plant-based anticancer agent in 
preclinical development, but, none of them have yet entered the stage of general use 
(Cragg and Newman, 2005). In response to this current need, the utilization of plants 
as one of the most valuable sources is considered as a significant approach for the 
discovery of effective and safe anticancer agents.  
 
Therefore, in this current investigation, a plant namely, Quercus infectoria (QI) galls 
has been selected due to its wide usage in traditional practices worldwide, 
particularly among Malaysian women. In addition, several scientific evidences have 
demonstrated the broad range of therapeutic properties associated with this plant 
including anti-inflammatory, antioxidant, antidiabetic, larvicidal, antibacterial, anti-
fungal and anticancer properties (Redwane et al., 2002; Kaur et al., 2004; Basri and 
Fan, 2005; Yamunarani et al., 2005; Kaur et al., 2008; Hasmah et al., 2010; Saini 
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and Patil, 2012). Based on the literatures available, there are limited informations and 
studies that reported the potential of this plant as anticancer agent. Moreover, 
mechanisms of action rely behind its anticancer activity is not well described by 
previous investigators.  
 
The ability of chemotherapeutic drugs to inhibit proliferation of cancer cells via 
apoptosis has been suggested as an important feature in the development of new 
cancer therapy (D’Agostini et al., 2005). Apoptosis is a form of cell death, where 
cells commit to suicide in natural way without affecting their surrounding cells to 
remove damage, senescent and unwanted cells (Huppertz and Herrler, 2005; 
Exbrayat et al., 2012). The acquired ability of cancer cells to evade apoptosis 
represents a main causative factor in the growth and progression of cancer (Hanahan 
and Weinberg, 2000; Zivny et al., 2010). Although abundant of anticancer agents 
targeting apoptosis under studies, majority of them are still in preclinical 
development due to low specificity and susceptibility to drug resistance (Russo et al., 
2006). Therefore, it is a reliable and promising strategy to target apoptosis as a 
mechanism for cancer therapy. 
 
Hence, the potential of QI galls as anticancer agent against cervical cancer (HeLa), 
ovarian cancer (Caov-3) and liver cancer (HepG-2) cell lines via apoptosis was 
studied. In this present study, phytochemicals and antioxidant activity related to its 
anticancer effects were also elucidated. 
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1.2 General objective 
The aim of this study is to determine the ability of QI galls aqueous (QIA) and 
ethanol (QIE) extracts to selectively inhibit the proliferation of cervical cancer 
(HeLa), ovarian cancer (Caov-3) and liver cancer (HepG-2) cell lines without 
causing harmful effects towards normal cells. The most potent extract then chosen 
for the determination of mode of cell death (apoptosis), phytochemical screenings 
and antioxidant activity. 
 
1.3              Specific objectives 
The specific objectives of this study are: 
1) To extract QI galls using water and ethanol. 
2) To determine the antiproliferative activity of cells treated with QI galls extracts. 
3) To study the mode of cell death in cells treated with the most potent QI galls 
extract. 
4) To evaluate the antioxidant activity and phytochemicals groups of the most 
potent QI gall extract. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1              Cancer 
Cancer is a disease formed from uncontrolled growth and progression of abnormal 
cells beyond their normal boundaries (Rieger, 2004). This disease is caused by 
several factors which are classified into external and internal factors, may act 
together to initiate and promote carcinogenesis. Tobacco, chemicals, radiation, and 
infectious organisms are among the identified external factors, meanwhile, internal 
factors include inherited mutations, hormones, immune conditions, and mutations 
that occur from metabolism (Rieger, 2004). 
 
Primary cancer derived as tumour mass that developed at the origin where the 
conversion of normal cells into tumour cells occurs (Oppenheimer, 2006). 
Frequently, tumours or also known as neoplasms are benign and slow-growing 
masses that pressure rather than invade neighbouring tissues (Oppenheimer, 2006). 
However, if left untreated, benign tumours can become malignant in which the cells 
can detach from their origin and set up metastasis (secondary cancer) (Kainsa et al., 
2012). Generally, malignant tumours possess the ability to grow faster, invade 
adjacent tissue and colonize distant organs (Kainsa et al., 2012). Further comparisons 
of benign and malignant tumours are summarized in table 2.1. 
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Table 2.1: Comparisons between benign and malignant tumours (Walsh, 2002). 
 
 
 
Benign 
 
Malignant 
 
Cells Relatively normal and mature Little resembles to normal, 
poorly differentiated, atypical in 
size and shape, non-uniform and 
immature 
 
Growth Slow and restricted. Non-invasive 
of surrounding tissue, expansive 
and pushing aside normal tissue. 
Rapid and unrestricted. Invasive 
of surrounding tissue. 
 
 
 
Recurrence Rare Frequent 
 
Spread Localized and encapsulated. Metastasize via blood and 
lymph stream. 
 
Threat to 
host 
 
 
 
 
 
 
 
 
Prognosis favorable. The effects 
depend on size and location. May 
cause pressure on vital organs and 
obstruct a passageway, which is 
usually corrected by surgical 
excision of neoplasms. 
 
 
Threatens life due to its local 
vicious proliferation and 
formation of secondary 
neoplasms in other structures. 
Prognosis more favorable with 
early diagnosis and treatment 
when cells show less departure 
from the normal and there is no 
metastasis. 
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2.1.1           Incidences of cancer  
Cancer is a major public health burden in both developed and developing countries. 
According to International Agency for Research on Cancer (IARC) about 12.7 
million new cancer incidences in 2008 have been reported worldwide, of which 5.6 
million cases attributed by economically developed countries and 7.1 million in 
economically developing countries. This situation contributes to the 7.6 million of 
total deaths due to cancer which is about 21 000 cancer deaths a day. This global 
burden is expected to raise up to 21.4 million new cancer cases and 13.2 million 
cancer deaths by 2030 (American Cancer Society, 2011).  
 
In Malaysia, cancer was listed as third most deadly diseases after heart diseases and 
diseases of pulmonary circulation, and septicaemia, which account 11.28% of overall 
causes of diseases. Based on the National Cancer Registry, out of total 18 219 cancer 
cases, the incidence was higher in female population with 10 096 cases (55.4%) 
compared to 8, 123 cases (44.6%) have been diagnosed in male population (Zainal 
Ariffin and Nor Saleha, 2011). 
 
In this present study, three types of cancer originated from cervix, liver and ovary 
were focused due to their high mortality rate among male and female populations 
especially those in the developing regions. 
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2.1.1.1        Cervical cancer 
Cervical cancer is the third most frequent cancer in women and has been documented 
as second leading cause of fatality for 242 000 women in developing countries 
(American Cancer Society, 2011; Jemal et al., 2011). In Malaysia, cervical cancer 
has been reported as second most common cancer in female. Annual report 
demonstrated that 2145 of new cervical cancer cases has been diagnosed which 
contributed to 621 new cancer deaths among Malaysian women in 2012 (Teo, 2015). 
 
Cervical cancer is characterized as sexual transmitted disease which arises from 
human papillomaviruses (HPV) where 92.9% of reported incidences in human 
bearing HPV DNA (Bosch et al., 1995). So far, HPVs are classified into low-risk and 
high-risk of all 73 types based on their relationship with pre-neoplastic and 
malignant cervical lesions (De Villiers, 1989; De Villiers, 1994; Zur Hausen and De 
Villiers, 1994). Low-risk HPVs constitute of types 6 and 11 mostly observed in 
Condyloma accuminata and low-grade cervical intraepithelial neoplasia 1 (CIN1) 
(Rattray et al., 1996; Chan and Berek, 2007). On the other hand, high-risk HPVs 
such as types 16, 18, 31, 33, 35, 39, 56 and 58 frequently infect CIN2, CIN3 and 
invasive cervical carcinomas (Rattray et al., 1996). 
 
The transmission of HPV viruses can be reduced through sexual barrier by 
decreasing sexual partners and the consistently use of condom. In addition, cervical 
cancer is preventable by early detection and taking vaccination (Cain et al., 2009). 
Vaccines are recommended as an effective tool for primary prevention to avoid up to 
70% of HPV infections (Chan and Berek, 2007). Nonetheless, vaccines utilization is 
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costly and require appropriate infrastructure to preserve the vaccines (Cain et al., 
2009).  
 
Diagnosis and treatment at early stages provide a proficient treatment and longer 
survival times (Levi et al., 2000). There are numerous techniques offered for the 
diagnosis of cervical cancer based on the cytological and histological alterations 
namely invasive tissue biopsies, pap smear, the thin-prep cytological test (TCT), 
naked-eye visual inspection of the cervix with acetic acid, colposcopy and 
cervicography (Janicek and Averrete, 2001; Kesic, 2006).  
 
The risk of death due to cervical cancer however can be reduced through suitable 
treatment and follow up (Cain et al., 2009). Hysterectomy has remained as standard 
therapy for cervical cancer. Radical hysterectomy with lymph node dissection or 
pelvic radiotherapy provide 5-years survival of early stage cervical cancer (Cain et 
al., 2009). In constrast, chemoradiotherapy has serve as standard mechanisms for 
advance stages of cervical cancer with 5-years survival (Cain et al., 2009).  
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2.1.1.2        Ovarian cancer 
Ovarian cancer can be categorized into three subgroups based on aetiologies and 
clinical behaviour, known as: 
i. Epithelial cell tumour: is the most common ovarian cancer which 
make up over than 85% of all cases (Agarwal and Kaye, 2003). 
ii. Germ cell tumour: is rare which presents only 1% of all ovarian 
cancer and more frequent among 26 years old women (Norris and 
Jensen, 1972; Quirk and Natarajan, 2005). 
iii. Stromal cell tumour: rare and diagnosed in 50 years old patients 
(Quirk and Natarajan, 2005). 
 
Ovarian cancer is identified by its high mortality rate and has been reported as main 
cause of death in developed countries (Fasching et al., 2009). According to the 
World Health Organization GLOBOCAN, in year 2012 about 238 719 patients 
throughout the world has been diagnosed with ovarian cancer and has been recorded 
as fourth most regular cancer in Malaysia, make up 6.5% of all cancers in Malaysian 
women (Zainal Ariffin and Nor Saleha, 2011; Ferlay et al., 2012).  
 
Detection at early stages is complicated since this disease often does not show any 
symptoms until become highly developed, making prognosis for ovarian cancer is 
poor with 70% of patients are usually diagnosed with advanced stages (Kirwan et al., 
2002).  
 
Generally, ovarian cancer is treated by surgery and chemotherapy (Chan et al., 
2007). Initial surgery can reduce or remove the tumour mass, however, if tumour is 
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larger than 2 cm, the potential to survive for 12 to 16 months is lower compared to 
those with tumour less than 2 cm that have 40 to 45 months of survival (Mutch, 
2002). For over three decades, the requirement for more efficient and less toxic 
chemotherapeutic agent for ovarian cancer has brought first-line chemotherapy to 
undergo a series of evolutions (Agarwal and Kaye, 2003). Recently, intravenous-
platinum and taxane-based chemotherapy has been applied in clinical practices as a 
standard patients’ care following surgery (Ozols et al., 2003; Thigpen et al., 2005).  
 
Although combination treatment of surgery and chemotherapy have showed 
advantages in controlling the progression of ovarian cancer, recurrence and ultimate 
succumbing of this disease forces many researches to investigate for new approaches 
to improve the available treatment (Onda and Yoshikawa, 2011).  
 
2.1.1.3        Liver cancer 
Globally, liver cancer is fifth most frequent cancer and second leading cause of 
mortality in male, with 70% to 85% of total liver cancer burden accounted by 
hepatocellular carcinoma (HCC) (Jemal et al., 2011; Ferlay et al., 2012).  HCC has 
been reported as a leading cause of liver cancer mortality all over the world and the 
incidence is expected to further increase in future (Venook et al., 2010). It has been 
reported that 85% of liver cancer cases occur in developing parts of the world, where 
East and Southeast Asia are among the highest rates of liver cancer (American 
Cancer Society, 2011).  
 
Chronic infections of hepatitis B or hepatitis C viruses are the main cause of liver 
cancer, accounting for 80% of hepatocellular carcinoma (HCC) (Rosen, 2011; 
13 
 
Arzumanyan et al., 2013). HBV has been found as major risk factor of more than 
50% global HCC incidences including Malaysia (Nguyen et al., 2009; Norsa’adah 
and Nurhazalani-Zayani, 2013). In Malaysia, HCC is ranked as eighth most regular 
cancer among male with incidence rate is 3.6 per 100 000 persons (Tirunagari and 
Shaik, 2013). Other possible factors such as long-term exposure to some dietary 
carcinogens, obesity, alcoholism, diabetes, cirrhosis and tobacco smoking may be 
contributed to the development of this disease (Perz et al., 2006; Chuang et al., 
2009). 
 
Current days, various treatment options are accessible to address HCC patients 
depending on the stage of the disease. According to The Barcelona Clinic Liver 
Cancer (BCLC) staging system, HCC are categorized into four main categories 
known as early stage (stage 0-A), intermediate stage (stage B), advance stage (stage 
C) and end-stage (stage D) disease (Forner et al., 2012).  
 
Patients with early stage HCC (stage A-0) are those diagnosed with solitary lesions 
or up to three lesions < 3cm. Possible curative treatments for early stage HCC may 
include resection, liver transplantation, or ablation with 5-year survival of 50% to 
70%. Patients with early tumour are introduced to the surgical resection or liver 
transplantation for their treatment. While, patients bearing single asymptomatic HCC 
< 2 cm and lack of vascular invasion or satellites with functional liver (Child-Pugh 
class A) are classified under subgroup of very early HCC (stage 0). An excellent 
outcome with almost no risk of reccurence is feasible, if patients are subjected to 
ablation or resection (Forner et al., 2012). 
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Patients with single large asymptomatic HCCs without vascular invasion or 
extrahepatic spread are categorized as stage B. The survival among stage B patients 
are varies depending on the confounding factors with expected median survival is 16 
months and some of them may surpass 50 months median survival (Beaugrand  et 
al., 2003; Cabibbo et al., 2010; Burrel et al., 2012; Malagari et al., 2012). 
Chemoembolization is recommended as a suitable treatment for stage B HCC (Bruix 
and Sherman, 2011). 
 
Stage C applies to HCC patients that present vascular invasion or extrahepatic spread 
and the symptoms begin to appear in stage C patients. Around four to eight months 
of median survival is expected in patients without treatment and it has been shown 
that treatment with sorafenib may improve survival (Beaugrand et al., 2003; Llovet 
et al., 2008; Cheng et al., 2009; Cabibbo et al., 2010). 
 
Patients diagnosed with stage D HCC is regarded as terminal stage where prognosis 
is dismal and expected survival is less than three months. Patients within this stage 
normally offered with the best palliative care (Forner et al., 2012). BCLC staging 
system and available treatment strategy for HCC patients are summarized in Figure 
2.1. 
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Figure 2.1: BCLC staging system and treatment strategy for HCC patients (adapted 
from Forner et al., 2012). 
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2.1.2           Cancer chemotherapy 
The application of chemotherapy in the cancer treatment begins in the late 1940s to 
treat advanced lymphoma (Gilman, 1963). Since then, over 50 licensed drugs have 
been introduced in the clinical use for the management of cancer (Brighton and 
Wood, 2005). Chemotherapy is the most frequent used in advanced cancer and 
usually adopted as an adjunct to surgery for the treatment of primary cancer in order 
to improve cure rates (Corrie, 2007; Sakuramoto et al., 2007). Chemotherapy 
following surgical resection which is regularly introduced to the patients with high 
risk of recurrence is called adjuvant chemotherapy (Corrie, 2007). Meanwhile, 
neoadjuvant chemotherapy is normally used for the treatment of localized cancer 
before planned curative surgery (Corrie, 2007). Sometimes, chemotherapy as well 
used in combination with radiotherapy (Corrie, 2007). 
 
Generally, chemotherapy drugs are classified according to their biochemical 
properties or cell cycle effects. Those categorized in the same biochemical class 
which include alkylating agents, antimetabolites, antitumour antibiotics, 
topoisomerase inhibitors and tubulin-binding drugs share similar mechanism of 
action (see Table 2.2) (Caley and Jones, 2012). While classification based on the cell 
cycle specificity is influenced by how drugs are scheduled and combined. Certain 
chemotherapy agents like antibiotics, antimetabolites, taxoids, vinca alkaloids from 
different class, except for alkylating agents have phase-specific activity on the cell 
cycle (see Figure 2.2) (Caley and Jones, 2012).  
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Chemotherapy exerts their effects by interfering with the biochemical process that is 
implicated or devoted to cellular replication and cause selective cell death (Osiecki, 
2002). Within this process, the rapidly dividing and fast growing cells, by which 
cancer cells are differentiated from normal cells, are recognized by chemotherapeutic 
drugs to be executed by apoptosis (Caley and Jones, 2012; Sak, 2012). 
Unfortunately, the rapidly growing normal cells including blood forming cells and 
epithelial cells, and tissue with metabolic functions and substantial blood flow such 
as liver and kidney as well targeted by the non-selective action of chemotherapy 
drugs, leading to undesirable side effects which become a major clinical problem, 
whereas toxicity often restricts the efficacy of anticancer agents (Johnstone et al., 
2002; Kovacic, 2007).  
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Table 2.2: Biochemical classification of chemotherapy drugs (Caley and Jones, 
2012). 
 
Drug class Mechanism of action  Examples 
 
Alkylating agents Have the ability to form 
covalent bond with molecules 
including protein, DNA and 
RNA. 
Cisplatin,  
carboplatin, 
chlorambucil, 
cyclophosphamide, 
ifosfamide. 
 
Anti-metabolites Impede DNA or RNA 
synthesis by either blocking 
enzyme required for DNA 
synthesis or become 
incorporated into DNA or 
RNA. 
 
5-Fluorouracil, 
Methotrexate, 
Pemetrexed, 
Mercaptopurine, 
Gemcitabine. 
Anti-tumor antibiotics Intercalate DNA at specific 
sequences and producing free 
radicals which results strand 
breakage. 
Bleomycin, 
Anthracyclines 
(doxorubicin, 
epirubicin). 
 
Topoisomerase inhibitors Uncoiling DNA during 
replication. 
Topoisomerase I 
(irinotecan, 
tapotecan) 
Topoisomerase II 
(etoposide). 
 
Tubulin-binding drugs Bind to tubilin to prevent the 
formation or disassembly of 
microtubules. 
Vinca alkaloids 
(vincristine, 
vinorelbine), 
Taxoids (docetaxel, 
paclitaxel) 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: The action of 
specific phases (G1, S, G2 and M) of the cell cycle, with the action of alkylating 
agent is non-specific to any phases
 
 
 
 
 
 
 
 
 
 
 
 
19 
certain chemotherapy agents from different classes 
 (adapted from Caley and Jones, 2012)
on the 
. 
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2.1.2.1        Cisplatin as standard chemotherapeutic drugs 
Cisplatin or also known as cis-diamminedichloroplatinum (II), or cis-DDP (Figure 
2.3) is one of the most potent chemotherapy drugs that have wide application against 
various types of cancer including testicular, ovarian, cervical, head and neck, 
esophageal, and non-small-cell lung cancers (Einhorn, 2002; Scagliotti et al., 2008; 
Gupta et al., 2009; Helm and States, 2009; Lee et al., 2009; Florea and Büsselberg, 
2011). This subtype of alkylating agent exerts its antitumour activity through its 
interaction with DNA. Cisplatin covalently bind at the N7 position of purine bases of 
the DNA to form primarily 1,2-intrastrand adducts between neighbouring guanosine 
residues, and a small number of interstrand and monofunctional Pt-DNA adducts. 
This results to DNA damage which eventually disturbs the normal cellular process 
such as transcription and replication. As the cell arrest occurs, the Pt lesions are 
either removed by nucleotide excision repair or apoptosis is triggered (Woźniak and 
Błasiak, 2002). 
 
Many of cancer patients bearing different forms of cancer have been successfully 
treated by cisplatin with better prognosis and reduced life threatening including 
sarcoma cancers, cancers of soft tissue, bones, muscles, and blood vessels (Florea 
and Büsselberg, 2011). It was found to be the most effective against testicular cancer 
with cure rates greater than 90% and approaching nearly 100% in early stage cases 
(Einhorn, 2002). Positive impact following cisplatin administration, though 
accompanied by toxic side effects and tumor resistance which have limits its usage.  
The toxic side effects related to the administration of cisplatin identified as 
nephrotoxicity (kidney damage), emetogenesis (vomiting and nausea), 
myelosuppression (bone marrow suppression), ototoxicity (hearing loss), 
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immunosuppression (decreased response to infection) and neurotoxicity (neuron 
damage) (Desoize and Madoulet, 2002; Florea and Büsselberg, 2006; Günes et al., 
2009; Shah and Dizon, 2009; Tsang et al., 2009).  
 
Dealing with these problems, many considerable efforts have been made to improve 
the efficacy, increase sensitivity and reduce the toxicity implicated with the 
chemotherapeutic drugs. Discovery of new anticancer agent from natural sources has 
become a trending strategy. Among them, plants provide a valuable source for the 
development of effective and safer anticancer agent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Molecular structure of cisplatin (adapted from Woźniak and Błasiak, 
2002). 
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2.2      Plant as source of anticancer agent 
Recently, alternative medicine from plant sources have been accepted and 
acknowledged by modern people. Not only used as part of healthcare regimes, plant 
also served as natural-based therapy for patients with chronic diseases such as 
diabetes, hypertension and cancer. For example, more than 60% of cancer patients 
consume vitamins or herbs as an alternative treatment (Sivalokanathan et al., 2005; 
Madhuri and Pandey, 2008).  
 
Abundant of scientific articles have reported the wide spectrum of therapeutic effects 
associated with plant especially in treating cancer. For example, eurycomanone, a 
plant compound isolated from Eurycoma longifolia Jack inhibit the proliferation of 
hepatocellular carcinoma (HepG-2) cell line via apoptosis (Zakaria et al., 2009).  
 
Until now, in the major amount of potential anticancer compounds originated from 
plants, only 1-10% of 250 000 to 500 000 of plant species in this world have been 
chemically and pharmacologically studied for their potential therapeutic values 
(Verpoorte, 2000).  Therefore, to maximize the possibility of discovering effective 
drugs for the treatment of cancer, the utilization of plant in this present study is 
realistic and fulfills the current requirement towards new chemotherapeutic agent 
that should be (Hoekman et al., 1999): 
 
i.              Effective 
ii. Highly selective for cancer cells (no harmful effects towards normal 
cells) 
iii. Less or no toxicity effects 
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iv. No negative impact on anticancer therapy 
v. Minimal side effects 
 
2.2.1      Quercus infectoria galls   
There are about 600 species of oak trees of the Family Fagaceae distributed in a 
variety of habitats such as seacoast, mountain slopes and wet lowlands of the North 
Temperate Zone (Khouzami et al., 2009).   
 
Quercus infectoria Olivier (QI) of the family Fagaceae is a small tree (4 to 6 feet tall) 
local to the Greece, Asia Minor, Syria and Iran (Basri and Fan, 2005; Olfat and 
Pourtahmasi, 2010). The tree shoot bearing galls, an abnormal growth formed from 
the attack of the gall-wasp called Cypnis gallae-tinctoria. The galls which are 
commonly known as manjakani in Malaysia is rounded hard body with 1-1.5 cm in 
diameter. The numerous horny protuberances on smooth external surface giving it’s 
a rough touch. Appear as greyish-brown to brownish-black on its external and yellow 
in colour of the inner surface. The present of pores on it’s uneven surface indicates  
infection (Figure 2.4) (Shrestha et al., 2014).  
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Figure 2.4: The physical morphology of QI galls. 
 
 
 
 
 
 
 
 
 
 
 
 
